About this Journal Submit a Manuscript Table of Contents
Thrombosis
Volume 2010 (2010), Article ID 280731, 9 pages
http://dx.doi.org/10.1155/2010/280731
Review Article

New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty

Department of Orthopaedic Surgery, Roper Hospital, Charleston Orthopaedic Associates, 1012 Physicians Drive, Charleston, SC 29414, USA

Received 16 March 2010; Revised 28 May 2010; Accepted 6 June 2010

Academic Editor: Gualtiero Palareti

Copyright © 2010 Richard J. Friedman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Kurtz, K. Ong, E. Lau, F. Mowat, and M. Halpern, “Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030,” Journal of Bone and Joint Surgery American, vol. 89, no. 4, pp. 780–785, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. B. AlBuhairn, D. Hind, and A. Hutchinson, “Antibiotic prophylaxis for wound infections in total joint arthroplasty : a systematic review,” Journal of Bone and Joint Surgery British, vol. 90, no. 7, pp. 915–919, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. W. H. Geerts, D. Bergqvist, G. F. Pineo et al., “Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, supplement, pp. 381S–453S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Warwick, R. J. Friedman, G. Agnelli et al., “Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events,” Journal of Bone and Joint Surgery British, vol. 89, no. 6, pp. 799–807, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. American Academy of Orthopaedic Surgeons, “American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty,” 2007, http://www.aaos.org/Research/guidelines/PE_guideline.pdf.
  6. P. Prandoni, A. W. A. Lensing, A. Cogo et al., “The long-term clinical course of acute deep venous thrombosis,” Annals of Internal Medicine, vol. 125, no. 1, pp. 1–7, 1996. View at Scopus
  7. C. Kearon, “Natural history of venous thromboembolism,” Circulation, vol. 107, no. 23, supplement, pp. I22–I30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. W. P. Gorman, K. R. Davis, and R. Donnelly, “ABC of arterial and venous disease. Swollen lower limb-1: general assessment and deep vein thrombosis,” British Medical Journal, vol. 320, no. 7247, pp. 1453–1456, 2000. View at Scopus
  9. A. M. Asbeutah, A. Z. Riha, J. D. Cameron, and B. P. McGrath, “Five-year outcome study of deep vein thrombosis in the lower limbs,” Journal of Vascular Surgery, vol. 40, no. 6, pp. 1184–1189, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Imberti, C. Dall'asta, and M. G. Pierfranceschi, “Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review,” Internal and Emergency Medicine, vol. 4, no. 6, pp. 471–477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Agnelli and C. Becattini, “New oral anticoagulants: just a new therapeutic option or a real breakthrough?” Internal and Emergency Medicine, vol. 4, no. 6, pp. 455–457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. V. V. Kakkar, T. P. Corrigan, and D. P. Fossard, “Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial,” The Lancet, vol. 2, no. 7924, pp. 45–51, 1975. View at Scopus
  13. S. Sagar, D. Nairn, J. D. Stamatakis, et al., “Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement,” The Lancet, vol. 1, no. 7970, pp. 1151–1154, 1976. View at Scopus
  14. J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz, “Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, supplement, pp. 141S–159S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. W. H. Geerts, J. A. Heit, G. P. Clagett et al., “Prevention of venous thromboembolism,” Chest, vol. 119, no. 1, supplement, pp. 132S–175S, 2001. View at Scopus
  16. A. G. G. Turpie, “Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1238–1247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. R. Lassen, K. A. Bauer, B. I. Eriksson, and A. G. G. Turpie, “Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison,” The Lancet, vol. 359, no. 9319, pp. 1715–1720, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. K. A. Bauer, B. I. Eriksson, M. R. Lassen, and A. G. G. Turpie, “Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery,” The New England Journal of Medicine, vol. 345, no. 18, pp. 1305–1310, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Turpie, K. Bauer, B. Eriksson, and M. Lassen, “Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration,” Thrombosis and Haemostasis, vol. 90, no. 2, pp. 364–366, 2003. View at Scopus
  20. M. N. Levine, M. Gent, J. Hirsh et al., “Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery,” Archives of Internal Medicine, vol. 156, no. 8, pp. 851–856, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. R. J. Friedman, A. S. Gallus, F. D. Cushner, G. FitzGerald, and F. A. Anderson Jr., “Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty,” Current Medical Research and Opinion, vol. 24, no. 1, pp. 87–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. T. Cohen, V. F. Tapson, J.-F. Bergmann et al., “Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study,” The Lancet, vol. 371, no. 9610, pp. 387–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti, “Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition),” Chest, vol. 133, no. 6, supplement, pp. 160S–198S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. F. Shorr, E. A. Nutescu, E. Farrelly, R. Horblyuk, L. E. Happe, and M. Franklin, “Postdischarge oral versus injectable anticoagulation following major orthopedic surgery,” Annals of Pharmacotherapy, vol. 42, no. 9, pp. 1222–1228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Pradaxa®, “Summary of product characteristics," 2008, http://www.pradaxa.com/Include/media/pdf/Pradaxa_SPC_EMEA.pdf.
  26. Xarelto®, “Summary of product characteristics," 2009, http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf.
  27. C. Frost, Z. Yu, S. Nepal, R. Mosqueda-Garcia, and A. Shenker, “Apixaban, an oral direct factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy volunteers,” Journal of Thrombosis and Haemostasis, vol. 5, supplement 1, 2007, Abstract no. P-M-665.
  28. C. E. Frost, S. Nepal, Y. Barrett, and F. LaCreta, “Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban,” in Proceedings of the 22nd congress of the International Society on Thrombosis and Haemostasis, Boston, Mass, USA, July 2009, Abstract no. PP-M0-407.
  29. N. Raghavan, C. E. Frost, Z. Yu et al., “Apixaban metabolism and pharmacokinetics after oral administration to humans,” Drug Metabolism and Disposition, vol. 37, no. 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Frost, L. Lee, L. Y. Li, S. Nepal, A. Shenker, and R. A. Reeves, “Apixaban does not affect the pharmacokinetics of digoxin,” Journal of Clinical Pharmacology, vol. 47, no. 9, 2007, Abstract no. 60.
  31. L. Wang, D. Zhang, N. Raghavan et al., “In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome p450 phenotyping, inhibition, and induction studies,” Drug Metabolism and Disposition, vol. 38, no. 3, pp. 448–458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Carreiro and J. Ansell, “Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict,” Expert Opinion on Investigational Drugs, vol. 17, no. 12, pp. 1937–1945, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. R. Lassen, B. L. Davidson, A. Gallus, G. Pineo, J. Ansell, and D. Deitchman, “The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement,” Journal of Thrombosis and Haemostasis, vol. 5, no. 12, pp. 2368–2375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and R. J. Portman, “Apixaban or enoxaparin for thromboprophylaxis after knee replacement,” The New England Journal of Medicine, vol. 361, no. 6, pp. 594–604, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick, “Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial,” The Lancet, vol. 375, no. 9717, pp. 807–815, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Stangier, “Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate,” Clinical Pharmacokinetics, vol. 47, no. 5, pp. 285–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Stangier, H. Stähle, K. Rathgen, and R. Fuhr, “Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects,” Clinical Pharmacokinetics, vol. 47, no. 1, pp. 47–59, 2008. View at Scopus
  38. S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth, “The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans,” Drug Metabolism and Disposition, vol. 36, no. 2, pp. 386–399, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Stangier, B. I. Eriksson, O. E. Dahl et al., “Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement,” Journal of Clinical Pharmacology, vol. 45, no. 5, pp. 555–563, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. B. I. Eriksson, O. E. Dahl, L. Ahnfelt et al., “Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I,” Journal of Thrombosis and Haemostasis, vol. 2, no. 9, pp. 1573–1580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. B. I. Eriksson, O. E. Dahl, H. R. Büller et al., “A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial,” Journal of Thrombosis and Haemostasis, vol. 3, no. 1, pp. 103–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2178–2185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. B. I. Eriksson and R. Friedman, “Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty,” Clinical and Applied Thrombosis/Hemostasis, vol. 15, pp. 25S–31S, 2009.
  44. The RE-MOBILIZE Writing Committee, “The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery,” Journal of Arthroplasty, vol. 24, no. 1, pp. 1–9, 2009.
  45. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial,” The Lancet, vol. 370, no. 9591, pp. 949–956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. S. E. Wolowacz, N. S. Roskell, J. M. Plumb, J. A. Caprini, and B. I. Eriksson, “Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis,” Thrombosis and Haemostasis, vol. 101, no. 1, pp. 77–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. R. J. Friedman, O. E. Dahl, N. Rosencher, et al., “Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials,” Thrombosis Research. In press. View at Publisher · View at Google Scholar
  48. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf, “The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban—an oral, direct factor Xa inhibitor,” Blood, vol. 108, no. 11, 2006, Abstract no. 905.
  49. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck, “Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects,” Journal of Clinical Pharmacology, vol. 47, no. 2, pp. 218–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Weinz, T. Schwarz, D. Kubitza, W. Mueck, and D. Lang, “Metabolism and excretion of rivaroxaban, an oral, direct factor xa inhibitor, in rats, dogs, and humans,” Drug Metabolism and Disposition, vol. 37, no. 5, pp. 1056–1064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf, “Rivaroxaban (BAY 59-7939)—an oral, direct factor Xa inhibitor—has no clinically relevant interaction with naproxen,” British Journal of Clinical Pharmacology, vol. 63, no. 4, pp. 469–476, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf, “Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin,” Journal of Clinical Pharmacology, vol. 46, no. 9, pp. 981–990, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf, “Co-administration of rivaroxaban—a novel, oral, direct factor Xa inhibitor—and clopidogrel in healthy subjects,” European Heart Journal, vol. 28, supplement 1, p. 189, 2007, Abstract no. P1272.
  54. D. Kubitza, M. Becka, and M. Zuehlsdorf, “No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7939 and digoxin,” Journal of Clinical Pharmacology, vol. 46, no. 6, p. 702, 2006, Abstract no. 11.
  55. B. I. Eriksson, L. C. Borris, O. E. Dahl et al., “Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement,” Thrombosis Research, vol. 120, no. 5, pp. 685–693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. B. I. Eriksson, L. Borris, O. E. Dahl et al., “Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement,” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 121–128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. B. I. Eriksson, L. C. Borris, O. E. Dahl et al., “A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement,” Circulation, vol. 114, no. 22, pp. 2374–2381, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. A. G. G. Turpie, W. D. Fisher, K. A. Bauer et al., “BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study,” Journal of Thrombosis and Haemostasis, vol. 3, no. 11, pp. 2479–2486, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. B. I. Eriksson, L. C. Borris, R. J. Friedman et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2765–2775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. K. Kakkar, B. Brenner, O. E. Dahl et al., “Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial,” The Lancet, vol. 372, no. 9632, pp. 31–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. M. R. Lassen, W. Ageno, L. C. Borris et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2776–2786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. A. G. G. Turpie, M. R. Lassen, B. L. Davidson et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial,” The Lancet, vol. 373, no. 9676, pp. 1673–1680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. B. I. Eriksson, A. K. Kakkar, and A. G. G. Turpie, “Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement,” Journal of Bone and Joint Surgery British, vol. 91, no. 5, pp. 636–644, 2009. View at Scopus
  64. A. G. G. Turpie, M. R. Lassen, A. K. Kakkar, et al., “A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effect on symptomatic venous thromboembolism and death, and bleeding,” Haematologica, vol. 94, supplement 2, p. 212, 2009.
  65. R. J. Friedman, A. G. G. Turpie, M. R. Lassen, et al., “A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty,” in Proceedings of the 122nd Annual Meeting of the American Orthopaedic Association, Bonita Springs, Fla, USA, June 2009, Abstract no. 314.
  66. R. H. Fitzgerald Jr., T. E. Spiro, A. A. Trowbridge et al., “Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin,” Journal of Bone and Joint Surgery American, vol. 83, no. 6, pp. 900–906, 2001. View at Scopus
  67. A. Squizzato, F. Dentali, L. Steidl, and W. Ageno, “New direct thrombin inhibitors,” Internal and Emergency Medicine, vol. 4, no. 6, pp. 479–484, 2009. View at Publisher · View at Google Scholar · View at Scopus